It has been observed that approximately 60-80% of all the women who give birth experience Postpartum blues (PPB) also known as ‘baby blues’, and in about 10-15% of the women suffering from postpartum blues, the mild condition of baby blues worsens and advances to Postpartum Depression (PPD).
The total diagnosed Postpartum Depression (PPD) prevalent population in the seven major markets was found to be 1,134,800 in 2017, which is expected to increase further during the study period (2017-2030). The western countries have the highest Postpartum Depression prevalence; while the Asian countries account for a relatively comparable PPD preponderance.
The Market Size of Postpartum Depression in the seven major markets was estimated to be USD 138.75 Million in 2017, with the United states occupying for maximum PPD Market share.
The rise in Postpartum Depression prevalence and immense opportunities with only a single marketed therapy available are the key factors that are expected to drive the PPD market in the upcoming years.
The key players in the Postpartum Depression market include Sage Therapeutics, Marinus Pharmaceuticals and others.
For more information on Postpartum Depression Market visit:
https://www.delveinsight.com/blog/postpartum-depression-market/